Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662360 | 0.81 | TAAR1 (0.66) | TAAR1PRMT6CARM1PRMT8KDM1A | |
| SCHEMBL29455232 | 0.81 | TAAR1 (0.66) | TAAR1PRMT6CARM1PRMT8KDM1A | |
| SCHEMBL6473992 | 0.77 | TAAR1 (0.46) | TAAR1PRMT6CARM1PRMT8KDM1A | |
| Bromobenzene SCHEMBL6279145 | 0.72 | ALDH1A1 (0.50) | MAOAMAOBKDM4EMAPTMAPK1 | |
| Bromomethane SCHEMBL1844007 | 0.70 | OXTR (0.46) | CYP1A2CYP2D6MAOAMAOBHTR2B | |
| SCHEMBL1697126 | 0.68 | MAPT (0.64) | TAAR1PRMT6KDM4ECYP3A4MAPT | |
| SCHEMBL346944 | 0.68 | — | — | |
| SCHEMBL30349594 | 0.68 | — | — | |
| SCHEMBL10170816 | 0.68 | OXTR (0.52) | MAOAMAOBKDM4EMAPT | |
| SCHEMBL1420648 | 0.66 | CYP1A2 (0.62) | TAAR1KDM1ACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | TAAR1 781/4885PRMT6 4002/4885CARM1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.